Differentiating Between JAK/TYK2 Inhibition in Psoriasis (July 27, 2022 - Jul 27, 2023)

Differentiating Between JAK/TYK2 Inhibition in Psoriasis is organized by Paradigm Medical Communications, LLC.,,Release Date: July 27, 2022,Expiration Date: July 27, 2023,,Program Overview:,Psoriasis is an immune-mediated disease characterized by hyperproliferation of keratinocytes resulting in a red, itchy, scaling rash that negatively impacts quality of life for patients. In addition, systemic inflammation may manifest in psoriatic disease in the joints and spine, associated inflammatory bowel disease or uveitis, and metabolic or cardiovascular disease. Systemic treatments are available for moderate-to-severe psoriasis that target specific proinflammatory cytokines. These are associated with high levels of skin disease clearance and reduction of arthritis symptoms for patients. However, not all patients respond to, or can tolerate, current biologic agents; or disease progression can occur despite optimal therapy, fueling a need for additional novel therapies. Janus kinase (JAK) inhibitors target intracellular signaling pathways of multiple cytokines active in psoriatic disease. JAK inhibitors have demonstrated efficacy in psoriatic disease but have safety concerns associated with effects on hematopoiesis and reports that show increased risk of thrombotic and cardiovascular events and malignancy. Emerging tyrosine kinase 2 (TYK2) inhibitors offer greater specificity, and a potentially greater safety profile stemming from increased specificity and selectivity. Clinicians need to differentiate between JAK-mediated cytokines and TYK2-mediated cytokines, mechanisms of action (MOA), and potential safety effects of TYK2 versus JAK inhibitors. As data emerge, clinicians will need to consider outcomes with respect to mechanisms to inform future clinical application.,,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Compare cytokines mediated by JAKs with those mediated by TYK2 and their roles in the pathophysiology of psoriasis,• Distinguish between the MOA of JAK and TYK2 inhibitors and implications for the treatment of psoriasis,• Outline the potential roles of JAK and TYK2 inhibitors in the treatment of psoriasis.